Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5

Mavrakis, Konstantinos J., McDonald, E. Robert, Schlabach, Michael R., Billy, Eric, Hoffman, Gregory R., deWeck, Antoine, Ruddy, David A., Venkatesan, Kavitha +36 more·2016·Science

DOI 10.1126/science.aad5944

Cited by (623)

Items 301–400 of 623

MTAP Deletion in Oncogenesis: A Synthetic Lethality Scenario
Jordi Ahnert Rodon, Melissa Lynne Johnson, Ben George, Pooja Anil Shah, Kathryn Cecilia Arbour · 2026 · Cancer Research
An Isogenic Cell Line Panel for Sequence-Based Screening of Targeted Anti-Cancer Drugs
Ashley L. Cook, Nicolas Wyhs, Surojit Sur, Blair Ptak, Maria Popoli, Laura Dobbyn, Tasos Papadopoulos, Chetan Bettegowda, Nickolas Papadopoulos, Bert Vogelstein et al. · 2021 · iScience
Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (MTAP) loss
Maroun Bou Zerdan, Prashanth Ashok Kumar, Elio Haroun, Nimisha Srivastava, Jeffrey S. Ross, Abirami Sivapiragasam · 2023 · Oncotarget
PRMT5 as a Potential Therapeutic Target in MYC-Amplified Medulloblastoma
Devendra Kumar, Stuti Jain, Donald W. Coulter, Shantaram S. Joshi, Nagendra K. Chaturvedi · 2023 · Cancers
Toward Understanding Molecular Recognition between PRMTs and their Substrates
Owen M. Price, Joan M. Hevel · 2020 · Current Protein and Peptide Science
Transition state analogue of MTAP extends lifespan of APCMin/+ mice
Ross Firestone, Mu Feng, Indranil Basu, Karina Peregrina, Leonard H. Augenlicht, Vern L. Schramm · 2021 · Scientific Reports
Research progress in DNA damage response (DDR)-targeting modulators: From hits to clinical candidates
Binbin Cheng, Zongbao Ding, Yimeng Hong, Yaping Wang, Yingxing Zhou, Jianjun Chen, Xiaopeng Peng, Chunlai Zeng · 2025 · European Journal of Medicinal Chemistry
CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP -Deleted Cancer
Nikola Knoll, Sarah Masser, Blanka Bordas, Richard Y. Ebright, Guangyan Li, Devishi Kesar, Eliana Destefanis, Nicholas Kania, Diego J. Rodriguez, Jayu Jen et al. · 2025 · Cancer Research
High-throughput kinetics in drug discovery
Maria Filipa Pinto, Julija Sirina, Nicholas D. Holliday, Claire L. McWhirter · 2024 · SLAS DISCOVERY
Biomedical effects of protein arginine methyltransferase inhibitors
Mengtong Cao, Terry Nguyen, Jiabao Song, Yujun George Zheng · 2025 · Journal of Biological Chemistry
The catalytic efficiency of METTL16 affects cellular processes by governing the intracellular S-adenosylmethionine setpoint
Juliana N Flaherty, Enakshi Sivasudhan, Matthew Tegowski, Xing Zheng, Madeline M. McGinnis, Olga V. Hunter, Kyah M. Featherston, Komal Sethia, Benjamin P. Tu, Kate D. Meyer et al. · 2025 · Cell Reports
Expression and localisation of methylthioadenosine phosphorylase (MTAP) in oral squamous cell carcinoma and their significance in epithelial-to-mesenchymal transition
Yusuke Amano, Daisuke Matsubara, Atsushi Kihara, Hiroshi Nishino, Yoshiyuki Mori, Toshiro Niki · 2021 · Pathology
Modulation of Type I Interferon Responses to Influence Tumor-Immune Cross Talk in PDAC
Carlotta Cattolico, Peter Bailey, Simon T. Barry · 2022 · Frontiers in Cell and Developmental Biology
Deletion and downregulation of MTAP contribute to the motility of esophageal squamous carcinoma cells
Xiao-Yu Cheng, Zou Liu, Shang Li, Hong‐Qing Cai, Yu Zhang, Yan Cai, Xin Xu, Jia‐Jie Hao, Ming‐Rong Wang · 2017 · OncoTargets and Therapy
RIOK1 kinase activity is required for cell survival irrespective ofMTAPstatus
Alexandra Hörmann, Barbara Hopfgartner, Thomas Köcher, Maja Corcokovic, Teresa Krammer, Christoph Reiser, Gerd Bader, Junwei Shi, Katharina Ehrenhöfer, Simon Wöhrle et al. · 2018 · Oncotarget
Functional Genomics for Cancer Research: Applications In Vivo and In Vitro
Thomas A. O’Loughlin, Luke A. Gilbert · 2018 · Annual Review of Cancer Biology
The RioK1 network determines p53 activity at multiple levels
Michela Damizia, Gian Mario Moretta, Peter De Wulf · 2023 · Cell Death Discovery
Diagnostic performance of immunohistochemistry markers for malignant pleural mesothelioma diagnosis and subtypes. A systematic review and meta-analysis
Rafael Santiago Parra-Medina, Juan Pablo Castañeda-González, Viviana Chaves-Cabezas, Juan Pablo Álzate, Juan José Cháves · 2024 · Pathology - Research and Practice
De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression
Naveen Kumar Tangudu, Raquel Buj, Hui Wang, Jiefei Wang, Aidan R. Cole, Apoorva Uboveja, Richard S. Fang, Amandine Amalric, Baixue Yang, Adam G. Chatoff et al. · 2024 · Cancer Research Communications
SCR‐7952, a highly selective MAT2A inhibitor, demonstrates synergistic antitumor activities in combination with the S‐adenosylmethionine‐competitive or the methylthioadenosine‐cooperative protein arginine methyltransferase 5 inhibitors in methylthioadenosine phosphorylase‐deleted tumors
Zhiyong Yu, Yi Kuang, Liting Xue, Xuan Ma, Tingting Li, Linlin Yuan, Mengying Li, Grace Xue, Zhen Li, Feng Shii Tang et al. · 2024 · MedComm
PRMT5 inhibitors: Therapeutic potential in pancreatic cancer
Carolin Schneider, Valentina Spielmann, Christian Joerg Braun, Günter Schneider · 2025 · Translational Oncology
Metabolic Characterization of Antifolate Responsiveness and Non-responsiveness in Malignant Pleural Mesothelioma Cells
Yuzo Sato, Shiori Matsuda, Ami Maruyama, Joji Nakayama, Tomoyuki Miyashita, Hibiki Udagawa, Shigeki Umemura, Kazuyoshi Yanagihara, Atsushi Ochiai, Masaru Tomita et al. · 2018 · Frontiers in Pharmacology
Combined inhibition by PRMT5 and MAT2A demonstrates a strong synthetic lethality in MTAP homozygous-deficient glioma models
Zuoyu Jiang, Xuetao Li, Zongyu Xiao, Wenjuan Gan, Xuewen Zhang, Yang Zhang, Weichao Wang, E Qinzhi, Yu Huang, Qikun Shi et al. · 2025 · Cell Death Discovery
MTAP Expression by Immunohistochemistry: A Novel Biomarker in NSCLC
Magdalena M. Brune, Luca Roma, Obinna Chijioke, Ilaria Alborelli, Martin Zacharias, Lenard Bubendorf, Tatjana Vlajnic, Nikolaus Deigendesch, Julian Pollinger, Petra Hirschmann et al. · 2025 · Journal of Thoracic Oncology
Structure-Based Design and Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High Selectivity, Brain Penetration, and In Vivo Efficacy
Faridoon Faridoon, Jiyue Zheng, Tao Zhang, Shuilong Tong, Tao Liu, Jiuen Cui, Xu Haojie, Di Hu, Ying Shen, Yajing Yin et al. · 2024 · Journal of Medicinal Chemistry
Discovery of Potent, Highly Selective, and Orally Bioavailable MTA Cooperative PRMT5 Inhibitors with Robust In Vivo Antitumor Activity
Meng Zhang, Xiaoyu Ding, Zhongying Cao, Yilin Yang, Xiao Ding, Xin Cai, Man Zhang, Alexander M. Aliper, Feng Ren, Hongfu Lu et al. · 2025 · Journal of Medicinal Chemistry
Genomic Characterization of Chondrosarcoma Reveals Potential Therapeutic Targets
Michael J. Wagner, Erica Maria Pimenta, Nathan W. Sweeney, Elizabeth T. Loggers, Jesse L. Roberts, Elyse J. Brinkmann, Eleanor Y. Chen, Robert W. Ricciotti, Candace L. Haddox, Rachel Berg et al. · 2025 · JCO Precision Oncology
Emerging drugs for the treatment of chronic myelomonocytic leukemia
Jorge Ramos Perez, Guillermo Montalban Bravo · 2020 · Expert Opinion on Emerging Drugs
Clinicopathological and Prognostic Significance of PRMT5 in Cancers: A System Review and Meta-Analysis
Zhenzhen Liang, Lianchang Liu, Chaowei Wen, Heya Jiang, Tianxia Ye, Shumei Ma, Xiaodong Liu · 2021 · Cancer Control
Cryo-EM structure-based selection of computed ligand poses enables design of MTA-synergic PRMT5 inhibitors of better potency
Wei Zhou, Gaya Prasad Yadav, Xiaozhi Taro Yang, Feng Qin, Chenglong Li, Qiu‐Xing Jiang · 2022 · Communications Biology
Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer
Stephen Yiu Chuen Choi, Caroline F. Ribeiro, Yuzhuo Z. Wang, Massimo F. Loda, Stephen R. Plymate, Takuma Uo · 2022 · Biomolecules
Continuous Fluorescence Assays for Reactions Involving Adenine
Ross Firestone, Scott A. Cameron, Peter C. Tyler, Rodrigo Gay Ducati, Adam Z. Spitz, Vern L. Schramm · 2016 · Analytical Chemistry
MTAP deficiency confers resistance to cytosolic nucleic acid sensing and STING agonists
Jung-Mao Hsu, Chunxiao Liu, Weiya Xia, Chung‐Yu Chen, Wei‐Chung Cheng, Junwei Hou, Mien‐Chie Hung · 2025 · Science
MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies
Mihaela D. Aldea, Sean M. Lenahan, Marie-Anaïs Locquet, L. Liao, M. Gasparro, P.C. Gokhale, Maria‐Rosa Ghigna, D.N. Ionescu, Igor Odintsov, Kenneth H. Ngo et al. · 2026 · Annals of Oncology
Protein arginine methyltransferases in cancer: mechanisms, functions, and therapeutic opportunities
Yoonae Jeong, Yena Cho, Yong Kee Kim · 2026 · Journal of Biomedical Science
Multidisciplinary Standards and Evolving Therapies for Patients With Pancreatic Cancer
Rachael Ann Safyan, Eejung Kim, Emmelie N. Dekker, Marjolein Y.V. Homs, Andrew J. Aguirre, Bas Groot Koerkamp, Elena Gabriela Chiorean · 2024 · American Society of Clinical Oncology Educational Book
Arginine methylation in cancer: mechanisms and therapeutic implications
Yuanyuan Xu, Qihui Wu, Yuxiu Zhang, Yijin Gu, Hui Zhu, Xiaodan Fu, Anqi Li, Yimin Li · 2025 · Biomarker Research
Emerging target discovery and drug repurposing opportunities in chordoma
Daniel M. Freed, Josh Sommer, Nindo B. Punturi · 2022 · Frontiers in Oncology
Type I arginine methyltransferases are intervention points to unveil the oncogenic Epstein-Barr virus to the immune system
Gaëlle Angrand, Alicia Quillévéré, Nadège Loaëc, Van-Trang Dinh, Ronan Le Sénéchal, Rahima Chennoufi, Patricia Duchambon, Marc Keruzoré, Rodrigo Prado Martins, Marie‐Paule Teulade‐Fichou et al. · 2022 · Nucleic Acids Research
A CRISPR Path to Finding Vulnerabilities and Solving Drug Resistance: Targeting the Diverse Cancer Landscape and Its Ecosystem
Benjamin J. McLean, Aji Istadi, Teleri Clack, Mezzalina Vankan, Daniel Schramek, G. Gregory Neely, Marina Pajic · 2022 · Advanced Genetics
Discovery of novel methionine adenosyltransferase 2A (MAT2A) allosteric inhibitors by structure-based virtual screening
Tuomo Kalliokoski, Henna Kettunen, Esa T. T. Kumpulainen, Emilia Kettunen, Gabriel Thieulin‐Pardo, Lars Neumann, Maren Thomsen, Ralf Paul, Alina Malyutina, Μαρία Γεωργιάδου · 2023 · Bioorganic & Medicinal Chemistry Letters
Exploiting the passenger ACO1-deficiency arising from 9p21 deletions to kill T-cell lymphoblastic neoplasia cells
Laura González-Sánchez, María Cobos-Fernández, Pilar López‐Nieva, María Villa‐Morales, Konstantinos Stamatakis, Jose Manuel Cuezva, José Luis Marín‐Rubio, Irene Vázquez-Domínguez, Iria González-Vasconcellos, EDUARDO C. SALIDO et al. · 2019 · Carcinogenesis
Genetic drivers of vulnerability and resistance in relapsed acute lymphoblastic leukemia
Sydney X. Lu, Omar Ibrahim Abdel-Wahab · 2016 · Proceedings of the National Academy of Sciences
Prognostic significance of CA 125 and TPS levels after chemotherapy in ovarian cancer patients.
A. van Dalen, J Favier, L Baumgartner, Ute Hasholzner, Hwa de Bruijn, D Dobbler, V H Dombi, D. Fink, Maurizia Giai, Peter G. McGing et al. · 1999 · PubMed
Long read sequencing reveals a novel class of structural aberrations in cancers: identification and characterization of cancerous local amplifications
Yoshitaka Sakamoto, Liu Xu, Masahide Seki, Toshiyuki Yokoyama, Masahiro Kasahara, Yukie Kashima, Akihiro Ohashi, Yoko Shimada, Noriko Motoi, Katsuya Tsuchihara et al. · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
Polyamines at the crossroad between cell metabolism and epigenetic regulation in acute leukemias
Francesca Pirini, Anna Ferrari, Mouna Jandoubi, Irene Azzali, Davide Angeli, Rossana Mondrone, Chiara Bracci, Francesca Ruggieri, Giovanni Martinelli, Giorgia Simonetti · 2025 · Cell Death Discovery
PRMT5 deficiency in myeloid cells reprograms macrophages to enhance antitumor immunity and synergizes with anti-PD-L1 therapy
Shiyu Chen, Zheyi Chen, Bingqian Zhou, Yongyu Chen, Yiren Huang, Jian Ping Cao, Lisong Shen, Yingxia Zheng · 2025 · Journal for ImmunoTherapy of Cancer
Molecular Mechanisms of Tumor Progression and Novel Therapeutic and Diagnostic Strategies in Mesothelioma
Taketo Kato, Ichidai Tanaka, Heng Huang, Shoji Okado, Yoshito Imamura, Yuji Nomata, Hirofumi Takenaka, Hiroki Watanabe, Yuta Kawasumi, Keita Nakanishi et al. · 2025 · International Journal of Molecular Sciences
Systemic Therapy for Advanced Biliary Tract Cancers in 2026: Current Standard of Care and Emerging Therapeutic Strategies
Hyunseok Yoon, Changhoon Yoo · 2025 · Journal of Gastroenterology and Hepatology
Extracellular 5′-methylthioadenosine inhibits intracellular symmetric dimethylarginine protein methylation of FUSE-binding proteins
Baiqing Tang, Hyung‐Ok Lee, Sapna Gupta, Liqun Wang, Alison Kurimchak, James S. Duncan, Warren D. Kruger · 2022 · Journal of Biological Chemistry
Novel synthetic lethality drug target in urothelial bladder cancer based on MTAP genomic loss
Michael F. Basin, Gennady Bratslavsky, Nathan Nahhas, Alina Basnet, Hanan Goldberg, Andrea Necchi, Ethan S. Sokol, Shakti H Ramkissoon, Richard S.P. Huang, Jeffrey S. Ross et al. · 2022 · Urologic Oncology Seminars and Original Investigations
Research Progress on Small-molecule Inhibitors of Protein Arginine Methyltransferase 5 (PRMT5) for Treating Cancer
Chaohua Guo, Lintao Wu, Xumei Zheng, Lin Zhao, Xiaojia Hou, Zhijun Wang, Chun Han · 2023 · Current Topics in Medicinal Chemistry
Targeting MTAP increases PARP inhibitor susceptibility in triple-negative breast cancer through a feed-forward loop
Xiangyu Zeng, Fei Zhao, Xinyi Tu, Yong Zhang, Wen‐Bin Yang, Jing Hou, Qi Jiang, Shouhai Zhu, Zheming Wu, Yalan Hao et al. · 2025 · Journal of Clinical Investigation
PRMT5: A Promising Synthetical Lethal Target for MTAP-Deleted Cancers
Bang Li, Jin-Qi Yu, Zhenjiao Yang, Yuanxiang Wang · 2025 · Journal of Medicinal Chemistry
HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study
Ghanshyam H. Ghelani, Maroun Bou Zerdan, Joseph M Jacob, Philippe E. Spiess, R. Li, Andrea Necchi, Petros D. Grivas, Ashish M. Kamat, Natalie A. Danziger, Douglas I. Lin et al. · 2023 · Urologic Oncology Seminars and Original Investigations
Discovery of Potent and Oral Bioavailable MAT2A Inhibitors for the Treatment of MTAP-Deleted Tumors
Qun Li, Yang Zang, Dan An, Lifei Liu, Wen Jiang, Rongchen Liu, Jiangtao Su, Jun Jie Yang, Lie Li, Xuejun Zhang · 2023 · ACS Medicinal Chemistry Letters
Transcriptome‐wide gene expression outlier analysis pinpoints therapeutic vulnerabilities in colorectal cancer
Elisa Mariella, Gaia Grasso, Martina Miotto, Kristi Buzo, Nicole Megan Reilly, Pietro Andrei, Pietro Paolo Vitiello, Giovanni Crisafulli, Sabrina Arena, Giuseppe Rospo et al. · 2024 · Molecular Oncology
Mitoferrin2 is a synthetic lethal target for chromosome 8p deleted cancers
Stephan Krieg, Thomas D. Rohde, Tobias Rausch, Luise Butthof, Lena Wendler-Link, Christoph Eckert, Kai Breuhahn, Bruno Galy, Jan O. Korbel, Maximilian Billmann et al. · 2024 · Genome Medicine
Comparing loss of p16 and MTAP expression in detecting CDKN2A homozygous deletion in pleomorphic xanthoastrocytoma
M. Adelita Vizcaíno, Caterina Giannini, Rachael A. Vaubel, Aivi T. Nguyen, Jorge A. Trejo‐Lopez, Aditya Raghunathan, Sarah M. Jenkins, Robert Brian Jenkins, Cinthya J. Zepeda‐Mendoza · 2024 · Journal of Neuropathology & Experimental Neurology
Generation of focal mutations and large genomic deletions in the pancreas using inducible in vivo genome editing
Amrendra Kumar Mishra, Fatemeh Emamgholi, Zulrahman Erlangga, Björn Hartleben, Kristian Unger, Katharina Wolff, Ulrike Teichmann, Michael Kessel, Norman Woller, Florian Kühnel et al. · 2019 · Carcinogenesis
The Role of Chromatin-Associated Proteins in Cancer
Kristian Helin, Saverio Minucci · 2016 · Annual Review of Cancer Biology
Identification of miR-146a is Associated with the Aggressiveness and Suppresses Proliferation via Targeting CDKN2A in Breast Cancer
Yanping Zhang, Shi Ding, Jie Yang, Xingfeng Chen, Weilin Huang · 2018 · Pathology & Oncology Research
The glioma microenvironment and its impact on antitumor immunity
Landon John Hansen, Christopher Mitchell Jackson · 2025 · Neuro-Oncology Advances
Mitochondrial VHL rewires cell metabolism in hypoxia
Guobang Li, Wenfeng Pan, Long Wu, Zhiliang Cai, Haoming Chen, Xingui Wu, Tiantian Yu, Kun Liao, Hui Zhang, 温星桥 et al. · 2025 · Cell Metabolism
Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression
Sara Busacca, Qi Zhang, Annabel Jane Sharkey, Alan G. Dawson, David Allan Moore, David A. Waller, Apostolos Nakas, Carolyn Jones, Kelvin Cain, Jinli Luo et al. · 2021 · Scientific Reports
A pan-CRISPR analysis of mammalian cell specificity identifies ultra-compact sgRNA subsets for genome-scale experiments
Boyang Zhao, Yiyun Rao, Scott M. Leighow, Edward P. O’Brien, Luke A. Gilbert, Justin R. Pritchard · 2022 · Nature Communications
An immunohistochemical and molecular genetic study of 60 colorectal carcinoma brain metastases in pursuit of predictive biomarkers for cancer therapy
Jerzy P. Lasota, Maciej Kaczorowski, Małgorzata Chłopek, Justyna Miłek-Krupa, Magdalena Szczepaniak, Kris Ylaya, Miłosz Chodyna, Ewa Iżycka‐Świeszewska, Anna Katrin Scherping, Piotr Czapiewski et al. · 2025 · Human Pathology
Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer
Verónica Rendo, Snehangshu Kundu, Natallia Rameika, Viktor Ljungström, Richard Svensson, Kimmo Palin, Lauri A. Aaltonen, Ivaylo Stoimenov, Tobias Sjöblom · 2020 · Scientific Reports
9p21.3 Microdeletion involving CDKN2A/2B in a young patient with multiple primary cancers and review of the literature
Marlene Richter Jensen, Ulrik Kristoffer Stoltze, Thomas van Overeem Hansen, Mads Bak, Astrid Marie Sehested, Catherine Rechnitzer, René Mathiasen, David Scheie, Karen Bonde Larsen, Tina Elisabeth Olsen et al. · 2022 · Molecular Case Studies
High PRMT5 levels, maintained by KEAP1 inhibition, drive chemoresistance in high-grade serous ovarian cancer
Harun Öztürk, Fidan Seker-Polat, Neda Abbaszadeh, Yasemin Kingham, Sandra Oršulić, Mazhar Adli · 2025 · Journal of Clinical Investigation
MTA-Cooperative PRMT5 Inhibitors Are Efficacious in MTAP-Deleted Malignant Peripheral Nerve Sheath Tumor Models
Xiaochun Zhang, Dana C. Borcherding, Minjie Zhang, Yang Lyu, Guangfeng Wang, Kevin He, Gorkem Oztosun, Ishita Sachdeva, Liuzhan Yang, Kuangying Yang et al. · 2025 · Clinical Cancer Research
CDK4/6 inhibition in advanced chordoma: final results of the NCT PMO-1601 trial
Maria‐Veronica Teleanu, Christoph E. Heilig, Sebastian Pirmann, Rainer Hamacher, Sebastian Bauer, Verena I. Gaidzik, R. Mayer-Steinacker, Jude Al-Sabah, Sandra S.L. Roldan Pinzon, H. Süße et al. · 2025 · ESMO Open
Protein arginine methyltransferase 5 as a novel therapeutic target in solid tumors
Ping Song, Fan Yang · 2025 · Genes & Diseases
Integrative genomic identification of therapeutic targets for pancreatic cancer
Jimmy A. Guo, Dennis H. Gong, Kyle E. Evans, Kazuki Takahashi, Ananya D. Jambhale, Carina Shiau, Patrick Z. Yu, Steven Wang, Wenzhuo Wu, Seema Chugh et al. · 2025 · Cell Reports
CDKN2A deletion is associated with immune desertification in diffuse pleural mesothelioma
Federica Torricelli, Benedetta Donati, Veronica Manicardi, Mila Gugnoni, Francesca Reggiani, Gloria Manzotti, Pierluigi Di Chiaro, Cristian Ascione, Simonetta Piana, Riccardo Valli et al. · 2025 · Journal of Experimental & Clinical Cancer Research
Clinical Actionability of Genes in Gastrointestinal Tumors
Nadia Saoudi Gonzalez, Giorgio Patelli, Giovanni Crisafulli · 2025 · Genes
The Role of Drug-Metabolizing Enzymes in Synthetic Lethality of Cancer
Zekun Zeng, Wenfang Zheng, Peng Hou · 2022 · Pharmacology & Therapeutics
Frequent loss of FAM126A expression in colorectal cancer results in selective FAM126B dependency
Shuang Li, Ting Han · 2024 · iScience
Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib
Xiaonan Zhang, Natallia Rameika, Lei Zhong, Verónica Rendo, Margus Veanes, Snehangshu Kundu, Sandro Nuciforo, Jordan Dupuis, Muhammad Azhar, Ioanna Tsiara et al. · 2024 · EBioMedicine
Functional analysis of 3′-UTR hairpins supports a two-tiered model for posttranscriptional regulation ofMAT2Aby METTL16
Olga V. Hunter, Julio Cesar Ruiz, Juliana N Flaherty, Nicholas K. Conrad · 2023 · RNA
Targeting RNA binding proteins with small-molecule inhibitors: Advances, challenges, and therapeutic opportunities
Yuning Shi, Dazhi Feng, Jieya Zhou, Lihua Liu, Xinnan Li, Zhenwei Yuan, Jianbing Wu, Hong Yao · 2025 · Acta Pharmaceutica Sinica B
MTA-cooperative PRMT5 inhibitors from cofactor-directed DNA-encoded library screens
Jan Andersson, Sanne Cowland, Mikkel Vestergaard, Yajing Yang, Siyuan Liu, Fang Xie, Susmith Mukund, Sudipa Ghimire-Rijal, Chris Carter, Grace Chung et al. · 2025 · Proceedings of the National Academy of Sciences
Cytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal-like cancers
Tim Arnoldus, Alex v. Vliet, Onno B. Bleijerveld, Adriaan F. H. de Groot, Qinglin Piao, Niek Blomberg, Désirée Schatton, Jing Ming Dong, Susan E. van Hal-van Veen, Rolf Harkes et al. · 2025 · Nature Genetics
Tumor evolution-targeted nanomedicineEVT
Lingpu Zhang, Jia‐Zhen Yang, Dongsheng Tang, Hanchen Zhang, Jianxun Ding, Haihua Xiao · 2022 · Scientia Sinica Chimica
MTAP-ANRIL gene fusion promotes melanoma epithelial-mesenchymal transition-like process by activating the JNK and p38 signaling pathways
Zhuoying Lin, Yu Lei, Mingyao Wen, Qin He, Dean Tian, Huaping Xie · 2023 · Scientific Reports
Integrative analysis of copy number and gene expression data identifies potential oncogenic drivers that promote mammary tumor recurrence
Robert A. Jones, Roger A. Moorehead · 2018 · Genes Chromosomes and Cancer
Cancer biology functional genomics: From small RNAs to big dreams
Soumya Sundara Rajan, Katelyn R. Ludwig, Katherine L. Hall, Tamara L. Jones, Natasha J. Caplen · 2020 · Molecular Carcinogenesis
Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment
Youyou Zhang, Mu Xu, Jiao Yuan, Zhongyi Hu, Junjie Jiang, Yanrong Sun, Jie Sheng Huang, Yuxin Wang, Bingwei Wang, Jianfeng Shen et al. · 2024 · eLife
Selective targeting of TBXT with DARPins identifies regulatory networks and therapeutic vulnerabilities in chordoma
Umbaugh, Charles S., Groth, Marie, Erkut, Cihan, Lee, Kwang-Seok, Marinho, Joana, Linder, Simon, Iser, Florian, Kapp, Jonas N., Schroeter, Petra, Dolaner, Simay et al. · 2025 · Science Advances
Targeting PRMT5: Current Inhibitors and Emerging Strategies for Therapeutic Intervention
Zhihang Shen, Chenglong Li · 2025 · Processes
A BRET biosensor for measuring uncompetitive engagement of PRMT5 complexes in cells
Elisabeth M. Rothweiler, Ani Michaud, Jakub Stefaniak, Usha Singh, Brynwood B. Mikulsky, James D. Vasta, Michael Beck, Jennifer Wilkinson, Jennifer Ward, Catherine M. Rogers et al. · 2025 · Nature Communications
Unraveling the potential of targeting methionine metabolism in cancer
Bang-Qi Wang, Xu-Chu Li, Zhenyu Huo, Kai Zeng, Shen Chen, Yuning Wang, Yiming Zhu, Yuyang Huang, Jiatong Ding, Yuanting Cai et al. · 2026 · Cancer Letters
Gene fusions during the early evolution of mesothelioma correlate with impaired DNA repair and Hippo pathways
Maymun Jama, Min Zhang, Charlotte Poile, Apostolos Nakas, Annabel Jane Sharkey, Joanna Działo, Alan G. Dawson, Kudzayi H Kutywayo, Dean Anthony Fennell, Edward J. Hollox · 2023 · Genes Chromosomes and Cancer
New insight into targeting the DNA damage response in the treatment of glioblastoma
Tengfei ZHEN, Tianyu Sun, Baichen XIONG, Hui Liu, Lei Wang, Yao Chen, Haopeng Sun · 2024 · Chinese Journal of Natural Medicines
Substrate adaptors are flexible tethering modules that enhance substrate methylation by the arginine methyltransferase PRMT5
Cyrus Y. Jin, Moritz Hunkeler, Kathleen M. Mulvaney, William R. Sellers, Eric S. Fischer · 2025 · Journal of Biological Chemistry
Targeted Approaches to Treatment of Pleural Mesothelioma: A Review
Ibiayi Dagogo‐Jack · 2023 · JCO Precision Oncology
Alterations of histone modifications in cancer
Maha Mohamed Saber-Ayad, Wafaa S.H. Ramadan, Raafat El‐Awady · 2023 · Elsevier eBooks
Rewiring amino acids in cancer
Yiqing Zhang, Jianxin Lyu, Hezhi Fang · 2025 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Cracking the resistance code: The molecular reclassification of cancer and precision therapy strategies
Mina Nikanjam, Razelle Kurzrock · 2025 · Seminars in Cancer Biology
MTAP-Null Tumors: A Comprehensive Review on Synthetic Vulnerabilities and Therapeutic Strategies
Bavani Subramaniam, Wai Chin Chong, Aylar Babaei, Miriam Bornhorst, Chunchao Zhang, Roger J. Packer, Javad Nazarian · 2025 · Cells